You are here
Bernard Combe, MD, PhD
Bernard Combe is Professor of Rheumatology at Montpellier University and Head of the Rheumatology Department at Lapeyronie Hospital in Montpellier, France.
Professor Combe completed his medical education at Montpellier University and was subsequently awarded a research fellowship in clinical immunology at the University of Texas at San Antonio, USA. Professor Combe was elected twice to the National Board of Universities in France, of which he was president from 2010 to 2013. As an expert in the immunopathology of autoimmune diseases, particularly rheumatoid arthritis, Professor Combe has been an active member of two scientific units at Institut National de la Santé et de la Recherché Médicale (INSERM). Additionally, he has served as the Principal Investigator or Coordinator of 225 clinical trials throughout his professional career.
Professor Combe is a member of the EULAR Executive Committee ( since 2014) ,was a member of the scientific committee of the annual EULAR congress from 2006 to 2009 and has been an active participant in several European and/or North American task forces since 2004. In 2007 and 2015, he was Chair of the group committee for EULAR recommendations for the management of early arthritis. Additionally, he has for the last 12 years been a member of the executive committee of the French Society of Rheumatology (FSR), and served as the President of the FSR (2011-2013).
Professor Combe has published more than 370 original and review articles in peer-reviewed journals. He is the Editor of La Lettre du Rhumatologue, and a member of the editorial board of Annals of the Rheumatic Diseases. He was Associate Editor of Arthritis & Rheumatology and was elected in July 2014 as the Editor of RMD Open, the new EULAR journal.
Consultant/Advisor: Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Janssen Global Services, LLC; MSD & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; UCB, Inc.
Grant/Research Support: F. Hoffmann-La Roche Ltd; Pfizer Inc.; UCB, Inc.
Speakers’ Bureau: Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; MSD & Co., Inc.; Pfizer Inc.; Sanofi; UCB, Inc.